Alnylam Pharmaceuticals/$ALNY
1D1W1MYTD1Y5YMAX
Capital at risk
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Ticker
- $ALNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Cambridge, United States
- Website
- www.alnylam.com
ALNY Metrics
BasicAdvanced
$33B
44.42
$5.62
0.27
-
Price and volume
Market cap
$33B
Beta
0.27
52-week high
$495.55
52-week low
$197.81
Average daily volume
1.6M
Financial strength
Current ratio
3.055
Quick ratio
2.791
Long term debt to equity
1.981
Total debt to equity
2.206
Interest coverage (TTM)
3.52%
Profitability
EBITDA (TTM)
1,054.538
Gross margin (TTM)
79.65%
Net profit margin (TTM)
16.13%
Operating margin (TTM)
20.81%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$1,920,000
Management effectiveness
Return on assets (TTM)
12.34%
Return on equity (TTM)
96.55%
Valuation
Price to earnings (TTM)
44.416
Price to revenue (TTM)
6.886
Price to book
24.65
Price to tangible book (TTM)
24.65
Price to free cash flow (TTM)
40.351
Free cash flow yield (TTM)
2.48%
Free cash flow per share (TTM)
6.185
Growth
Revenue change (TTM)
95.14%
Earnings per share change (TTM)
-353.96%
3-year revenue growth (CAGR)
57.17%
10-year revenue growth (CAGR)
66.17%
3-year earnings per share growth (CAGR)
-13.27%
10-year earnings per share growth (CAGR)
2.86%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
Analyst projections of the future price of Alnylam Pharmaceuticals stock.
Bulls say / Bears say
Alnylam’s commercial engine is scaling quickly: Q2 2026 product revenue rose 74% year on year to $1.172 billion, including $1.03 billion from the TTR franchise. AMVUTTRA’s ATTR-cardiomyopathy launch is the main driver and gives the company a sizeable base for further growth. (Alnylam Pharmaceuticals)
Recent HELIOS-B analyses found vutrisiran’s benefits on mortality and recurrent cardiovascular events were consistent in patients taking tafamidis and those not taking it. That supports AMVUTTRA’s potential as a broad treatment rather than a niche option for untreated patients. (Alnylam Pharmaceuticals)
Alnylam has several potential growth levers beyond current TTR sales, with three pivotal trials under way and four further clinical readouts expected in 2026. Its raised collaboration and royalty guidance, helped by stronger LEQVIO royalties and Roche cost reimbursement, also adds support while the pipeline matures. (Alnylam Pharmaceuticals, Alnylam Pharmaceuticals)
Management cut 2026 TTR revenue guidance to $4.2 billion-$4.5 billion from $4.4 billion-$4.7 billion after early second-line AMVUTTRA demand normalised. The reset suggests the initial launch surge overstated the near-term growth rate. (Alnylam Pharmaceuticals)
BridgeBio’s rival ATTR-CM drug Attruby generated $222.4 million in Q2 and more than tripled year on year, showing that AMVUTTRA still faces a credible first-line competitor. Investors also remain concerned about how well AMVUTTRA will hold its position against protein stabilisers, despite the failure of a competing silencer trial. (The Motley Fool, Endpoints News)
The longer-term growth story still depends on clinical and regulatory execution across unproven programmes such as nucresiran, zilebesiran and the newer neurological, bleeding-disorder and obesity assets. Alnylam is advancing multiple pivotal studies, but a failed readout or delay could expose the company’s heavy reliance on AMVUTTRA. (Alnylam Pharmaceuticals, Alnylam Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALNY News
AllArticlesVideos
Funds containing ALNY
AllUSDGBPEUR
Fund name | Fund size | $ALNY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 2.19% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 2.19% |
Amundi S&P 500£500G | £6.6B | 0.63% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.55% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.